Major contribution of the P2Y1 receptor in purinergic regulation of tnfα-induced vascular inflammation

Circulation

Volumn 123, Issue 21, 2011, Pages 2404-2413

  Zerr, Murielle ^a   Hechler, Béatrice ^a   Freund, Monique ^a   Magnenat, Stéphanie ^a   Lanois, Isabelle ^a   Cazenave, Jean Pierre ^a   Léon, Catherine ^a   Gachet, Christian ^a  

^a UNIVERSITÉ DE STRASBOURG   (France)

Author keywords

apolipoproteins; atherosclerosis; endothelial cells; inflammation; receptors, purinergic P2

Indexed keywords

4 (2 IODO 6 METHYLAMINO 9H PURIN 9 YL) 2 PHOSPHONOOXYBICYCLO[3.1.0]HEXANE 1 METHANOL; ACTIVATING TRANSCRIPTION FACTOR 2; APOLIPOPROTEIN E; CELL ADHESION MOLECULE; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1BETA; MITOGEN ACTIVATED PROTEIN KINASE P38; PADGEM PROTEIN; PURINERGIC P2Y1 RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1; AUTACOID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ADHESION; CELL ISOLATION; CELL MIGRATION; CONTROLLED STUDY; ENDOTHELIUM CELL; FEMORAL ARTERY; HEMATOPOIETIC CELL; LEUKOCYTE; MALE; MONOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; THROMBOCYTE; VASCULITIS; ACUTE DISEASE; ANIMAL; ARTERITIS; ATHEROSCLEROSIS; BONE MARROW CELL; C57BL MOUSE; CELL CULTURE; CELL MOTION; COMPARATIVE STUDY; CYTOLOGY; GENETICS; HISTOCOMPATIBILITY; MESENTERIC VEIN; METABOLISM; MOUSE MUTANT; PATHOLOGY; PHYSIOLOGY; VASCULAR ENDOTHELIUM;

ACUTE DISEASE; ANIMALS; APOLIPOPROTEINS E; ARTERITIS; ATHEROSCLEROSIS; BONE MARROW CELLS; CELL MOVEMENT; CELLS, CULTURED; ENDOTHELIUM, VASCULAR; FEMORAL ARTERY; INFLAMMATION MEDIATORS; MALE; MESENTERIC VEINS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; RECEPTORS, PURINERGIC P2Y1; TRANSPLANTATION CHIMERA; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79958166577     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.110.002139     Document Type: Article

References (44)

1. Libby P, Okamoto Y, Rocha VZ, Folco E. Inflammation in atherosclerosis: transition from theory to practice. Circ J. 2010;74:213-220.
2. Gerrity RG. The role of the monocyte in atherogenesis: II: migration of foam cells from atherosclerotic lesions. Am J Pathol. 1981;103:191-200. (Pubitemid 11112974)
3. Weber C, Zernecke A, Libby P. The multifaceted contributions of leukocyte subsets to atherosclerosis: lessons from mouse models. Nat Rev Immunol. 2008;8:802-815.
4. Ley K, Laudanna C, Cybulsky MI, Nourshargh S. Getting to the site of inflammation: the leukocyte adhesion cascade updated. Nat Rev Immunol. 2007;7:678-689. (Pubitemid 47327397)
5. Frenette PS, Wagner DD. Insights into selectin function from knockout mice. Thromb Haemost. 1997;78:60-64. (Pubitemid 27289216)
6. Rao RM, Yang L, Garcia-Cardena G, Luscinskas FW. Endothelialdependent mechanisms of leukocyte recruitment to the vascular wall. Circ Res. 2007;101:234-247. (Pubitemid 47344073)
7. Madge LA, Pober JS. TNF signaling in vascular endothelial cells. Exp Mol Pathol. 2001;70:317-325. (Pubitemid 32607204)
8. Burnstock G. Purinergic signaling and vascular cell proliferation and death. Arterioscler Thromb Vasc Biol. 2002;22:364-373. (Pubitemid 34218740)
9. Di Virgilio F, Chiozzi P, Ferrari D, Falzoni S, Sanz JM, Morelli A, Torboli M, Bolognesi G, Baricordi OR. Nucleotide receptors: an emerging family of regulatory molecules in blood cells. Blood. 2001;97: 587-600. (Pubitemid 32113390)
10. Abbracchio MP, Burnstock G, Boeynaems JM, Barnard EA, Boyer JL, Kennedy C, Knight GE, Fumagalli M, Gachet C, Jacobson KA, Weisman GA. International Union of Pharmacology LVIII: update on the P2Y G protein-coupled nucleotide receptors: from molecular mechanisms and pathophysiology to therapy. Pharmacol Rev. 2006;58:281-341. (Pubitemid 44394905)
11. Burnstock G. Pathophysiology and therapeutic potential of purinergic signaling. Pharmacol Rev. 2006;58:58-86.
12. Seiffert K, Ding W, Wagner JA, Granstein RD. ATPgammaS enhances the production of inflammatory mediators by a human dermal endothelial cell line via purinergic receptor signaling. J Invest Dermatol. 2006;126: 1017-1027.
13. Seye CI, Yu N, Jain R, Kong Q, Minor T, Newton J, Erb L, Gonzalez FA, Weisman GA. The P2Y2 nucleotide receptor mediates UTP-induced vascular cell adhesion molecule-1 expression in coronary artery endothelial cells. J Biol Chem. 2003;278:24960-24965. (Pubitemid 37548657)
14. Seye CI, Yu N, Gonzalez FA, Erb L, Weisman GA. The P2Y2 nucleotide receptor mediates vascular cell adhesion molecule-1 expression through interaction with VEGF receptor-2 (KDR/Flk-1). J Biol Chem. 2004;279: 35679-35686. (Pubitemid 39100571)
15. Dawicki DD, McGowan-Jordan J, Bullard S, Pond S, Rounds S. Extracellular nucleotides stimulate leukocyte adherence to cultured pulmonary artery endothelial cells. Am J Physiol. 1995;268:L666-L673.
16. Seye CI, Kong Q, Erb L, Garrad RC, Krugh B, Wang M, Turner JT, Sturek M, Gonzalez FA, Weisman GA. Functional P2Y2 nucleotide receptors mediate uridine 5-triphosphate-induced intimal hyperplasia in collared rabbit carotid arteries. Circulation. 2002;106:2720-2726. (Pubitemid 35364928)
17. Ben Yebdri F, Kukulski F, Tremblay A, Sevigny J. Concomitant activation of P2Y(2) and P2Y(6) receptors on monocytes is required for TLR1/2-induced neutrophil migration by regulating IL-8 secretion. Eur J Immunol. 2009;39:2885-2894.
18. Gachet C. Regulation of platelet functions by P2 receptors. Annu Rev Pharmacol Toxicol. 2006;46:277-300. (Pubitemid 43271191)
19. Léon C, Hechler B, Freund M, Eckly A, Vial C, Ohlmann P, Dierich A, LeMeur M, Cazenave JP, Gachet C. Defective platelet aggregation and increased resistance to thrombosis in purinergic P2Y(1) receptor-null mice. J Clin Invest. 1999;104:1731-1737. (Pubitemid 30053190)
20. Fabre JE, Nguyen M, Latour A, Keifer JA, Audoly LP, Coffman TM, Koller BH. Decreased platelet aggregation, increased bleeding time and resistance to thromboembolism in P2Y1-deficient mice. Nat Med. 1999; 5:1199-1202. (Pubitemid 29474427)
21. Léon C, Freund M, Ravanat C, Baurand A, Cazenave JP, Gachet C. Key role of the P2Y(1) receptor in tissue factor-induced thrombin-dependent acute thromboembolism: studies in P2Y(1)-knockout mice and mice treated with a P2Y(1) antagonist. Circulation. 2001;103:718-723. (Pubitemid 32144201)
22. Lenain N, Freund M, Léon C, Cazenave JP, Gachet C. Inhibition of localized thrombosis in P2Y1-deficient mice and rodents treated with MRS2179, a P2Y1 receptor antagonist. J Thromb Haemost. 2003;1: 1144-1149.
23. Hechler B, Nonne C, Roh EJ, Cattaneo M, Cazenave JP, Lanza F, Jacobson KA, Gachet C. MRS2500 [2-iodo-n6-methyl-(n)-methanocarba-2-deoxyadenosine-3,5- bisphosphate], a potent, selective, and stable antagonist of the platelet P2Y1 receptor with strong antithrombotic activity in mice. J Pharmacol Exp Ther. 2006;316: 556-563. (Pubitemid 43130981)
24. Hechler B, Freund M, Ravanat C, Magnenat S, Cazenave JP, Gachet C. Reduced atherosclerotic lesions in P2Y1/apolipoprotein E doubleknockout mice: The contribution of non-hematopoietic-derived P2Y1 receptors. Circulation. 2008;118:754-763.
25. Dong QG, Bernasconi S, Lostaglio S, De Calmanovici RW, Martin-Padura I, Breviario F, Garlanda C, Ramponi S, Mantovani A, Vecchi A. A general strategy for isolation of endothelial cells from murine tissues: characterization of two endothelial cell lines from the murine lung and subcutaneous sponge implants. Arterioscler Thromb Vasc Biol. 1997;17: 1599-1604. (Pubitemid 27387783)
26. Schramm R, Menger MD, Schaefers HJ, Thorlacius H. Leukocyte adhesion in aorta and femoral artery in vivo is mediated by LFA-1. Inflamm Res. 2004;53:523-527. (Pubitemid 40110117)
27. Cuadrado A, Nebreda AR. Mechanisms and functions of p38 MAPK signalling. Biochem J. 2010;429:403-417.
28. Bradley JR. TNF-mediated inflammatory disease. J Pathol. 2008;214: 149-160. (Pubitemid 351160153)
29. Baud V, Karin M. Signal transduction by tumor necrosis factor and its relatives. Trends Cell Biol. 2001;11:372-377. (Pubitemid 32900529)
30. Brinkman BM, Telliez JB, Schievella AR, Lin LL, Goldfeld AE. Engagement of tumor necrosis factor (TNF) receptor 1 leads to ATF-2-and p38 mitogen-activated protein kinase-dependent TNF-alpha gene expression. J Biol Chem. 1999;274:30882-30886.
31. Reimold AM, Kim J, Finberg R, Glimcher LH. Decreased immediate inflammatory gene induction in activating transcription factor-2 mutant mice. Int Immunol. 2001;13:241-248. (Pubitemid 32123958)
32. Viemann D, Goebeler M, Schmid S, Klimmek K, Sorg C, Ludwig S, Roth J. Transcriptional profiling of IKK2/NF-kappa B-and p38 map kinase-dependent gene expression in TNF-alpha-stimulated primary human endothelial cells. Blood. 2004;103:3365-3373. (Pubitemid 38525666)
33. Peregrin S, Jurado-Pueyo M, Campos PM, Sanz-Moreno V, Ruiz-Gomez A, Crespo P, Mayor F Jr, Murga C. Phosphorylation of p38 by GRK2 at the docking groove unveils a novel mechanism for inactivating p38MAPK. Curr Biol. 2006;16:2042-2047. (Pubitemid 44604449)
34. Dangelmaier C, Jin J, Daniel JL, Smith JB, Kunapuli SP. The P2Y1 receptor mediates ADP-induced p38 kinase-activating factor generation in human platelets. Eur J Biochem. 2000;267:2283-2289. (Pubitemid 30220074)
35. Shen J, DiCorleto PE. ADP stimulates human endothelial cell migration via P2Y1 nucleotide receptor-mediated mitogen-activated protein kinase pathways. Circ Res. 2008;102:448-456. (Pubitemid 351651109)
36. Seeger FH, Sedding D, Langheinrich AC, Haendeler J, Zeiher AM, Dimmeler S. Inhibition of the p38 map kinase in vivo improves number and functional activity of vasculogenic cells and reduces atherosclerotic disease progression. Basic Res Cardiol. 2010;105:389-397.
37. Sarov-Blat L, Morgan JM, Fernandez P, James R, Fang Z, Hurle MR, Baidoo C, Willette RN, Lepore JJ, Jensen SE, Sprecher DL. Inhibition of p38 mitogen-activated protein kinase reduces inflammation after coronary vascular injury in humans. Arterioscler Thromb Vasc Biol. 2010;30:2256-2263.
38. Madonna R, Pandolfi A, Massaro M, Consoli A, De Caterina R. Insulin enhances vascular cell adhesion molecule-1 expression in human cultured endothelial cells through a pro-atherogenic pathway mediated by p38 mitogen-activated protein-kinase. Diabetologia. 2004;47:532-536. (Pubitemid 38491250)
39. Madonna R, Massaro M, Pandolfi A, Consoli A, De Caterina R. The prominent role of p38 mitogen-activated protein kinase in insulinmediated enhancement of VCAM-1 expression in endothelial cells. Int J Immunopathol Pharmacol. 2007;20:539-555. (Pubitemid 47531057)
40. Madonna R, Massaro M, De Caterina R. Insulin potentiates cytokine-induced VCAM-1 expression in human endothelial cells. Biochim Biophys Acta. 2008;1782:511-516.
41. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. 2002;105:1135-1143. (Pubitemid 34212626)
42. Libby P, Crea F. Clinical implications of inflammation for cardiovascular primary prevention. Eur Heart J. 2010;31:777-783.
43. Libby P. How our growing understanding of inflammation has reshaped the way we think of disease and drug development. Clin Pharmacol Ther. 2010;87:389-391.
44. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195-2207.